21st Oct 2021 17:55
Sensyne Health PLC - Oxford-based healthcare technology company - Says its licence and development partner, Excalibur Healthcare Services Ltd, has received European regulatory certification, which includes the UK, for its 'Test-To-Go' Covid-19 antigen testing system powered by Sensyne's MagnifEye. Excalibur and Sensyne will work to drive adoption and use throughout the European Economic Area and the UK in the use of Covid-19 lateral flow testing across commercial and government settings, it says.
Chief Executive Officer Paul Drayson says: "This is a major scientific achievement and, we believe, a world first in developing a regulated software application using state of the art AI to enhance the accuracy of lateral flow testing and reporting. This important milestone provides access to a key commercial market and potentially will have a major positive impact on improving the reporting of COVID lateral flow tests and supporting societies' recovery from the pandemic.
"This news underlines the significant potential of our MagnifEye technology which is helping to automate and improve the accuracy of reading images in many diagnostic testing and medical imaging applications."
Current stock price: 100.00 pence
Year-to-date change: down 11%
By Arvind Bhunjun; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
SENS.L